Christopher Morash1, Ilias Cagiannos. 1. Division of Urology, Department of Surgery, B3 Urology, The Ottawa Hospital, Ottawa, ON, K1Y 4E9, Canada. cmorash@ottawahospital.on.ca
Abstract
INTRODUCTION: High-risk clinical stage I NSGCT patients are at significant risk of harbouring occult metastatic disease. In these patients, treatment options consist of retroperitoneal lymph node dissection (RPLND) or two cycles of primary BEP chemotherapy. Both these options provide a nearly 100% cure rate. MATERIALS AND METHODS: We review the rationale for both treatments. CONCLUSIONS: Advantages of RPLND include high cure rate with single modality therapy eliminating the need for chemotherapy with its attendant long-term toxicities in the majority of patients.
INTRODUCTION: High-risk clinical stage I NSGCT patients are at significant risk of harbouring occult metastatic disease. In these patients, treatment options consist of retroperitoneal lymph node dissection (RPLND) or two cycles of primary BEP chemotherapy. Both these options provide a nearly 100% cure rate. MATERIALS AND METHODS: We review the rationale for both treatments. CONCLUSIONS: Advantages of RPLND include high cure rate with single modality therapy eliminating the need for chemotherapy with its attendant long-term toxicities in the majority of patients.
Authors: D Strumberg; S Brügge; M W Korn; S Koeppen; J Ranft; G Scheiber; C Reiners; C Möckel; S Seeber; M E Scheulen Journal: Ann Oncol Date: 2002-02 Impact factor: 32.976
Authors: Andrew J Stephenson; George J Bosl; Robert J Motzer; Michael W Kattan; Jason Stasi; Dean F Bajorin; Joel Sheinfeld Journal: J Clin Oncol Date: 2005-04-20 Impact factor: 44.544
Authors: C Bokemeyer; C C Berger; J T Hartmann; C Kollmannsberger; H J Schmoll; M A Kuczyk; L Kanz Journal: Br J Cancer Date: 1998-04 Impact factor: 7.640
Authors: C G Ruf; S Sachs; N Khalili-Harbi; H Isbarn; W Wagner; C Matthies; V Meineke; M Fisch; F K Chun; M Abend Journal: World J Urol Date: 2013-10-29 Impact factor: 4.226